EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study

Jenny Goudemand iD, Annie Borel-Derlon iD, Ségolène Claeyssens, Hervé Chambost, Guillaume Mourey, Annie Harroche, Sandrine Meunier iD, Céline Henriet, Thierry Leroi, Sophie Susen, Yohann Repesse iD

Haemophilia · 2025

DOI: 10.1111/hae.70129 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Haemophilia, 2025. Verfasst von Jenny Goudemand und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haemostasis and Transfusion, Lille University Hospital, Lille, France. Hauptthemen laut MEDLINE: von Willebrand Factor, von Willebrand Diseases, Factor VIII. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LFB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although clinical experience of a triple‐secured, plasma‐derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its use in children is less documented.

Aim

To explore the safety and efficacy of this concentrate in real‐life, in children

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Factorvon Willebrand DiseasesFactor VIIIHumansChildProspective StudiesChild, PreschoolMaleFemaleInfantProduct Surveillance, PostmarketingHemorrhageTreatment Outcome

Stichwörter der Autor:innen

Factor VIIIpaediatricreal‐life studyvon Willebrand diseasevon Willebrand factorvon Willebrand factor concentrate

Substanzen

von Willebrand FactorFactor VIII

Autor:innen und Institutionen

  • Department of Haemostasis and Transfusion, Lille University Hospital, Lille, France.
  • Haemophilia Treatment Centre, University Hospital of Caen, Caen, France.
  • Haemophilia Treatment Center, Purpan Hospital, Toulouse, France.
  • AP-HM, Department of Paediatric Haematology Oncology, Institut National De La Santé Et De La Recherche médicale, Institut national De La Recherche Agronomique, Centre Recherche En CardioVasculaire et Nutrition, Children…
  • Medical Biology Laboratory, Biological Haemostasis Department, CHU Besançon, Besançon, France.
  • CHU Besançon, SINERGIES (UR 4662), Université Marie et Louis Pasteur, Besançon, France.

ORCID-Profile: Jenny Goudemand, Annie Borel-Derlon, Sandrine Meunier, Yohann Repesse

Förderung

  • LFB

Zitieren

APA

Goudemand, J., Borel-Derlon, A., Claeyssens, S., Chambost, H., Mourey, G., Harroche, A., Meunier, S., Henriet, C., Leroi, T., Susen, S., & Repesse, Y. (2025). Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study. Haemophilia. https://doi.org/10.1111/hae.70129

Vancouver

Goudemand J, Borel-Derlon A, Claeyssens S, Chambost H, Mourey G, Harroche A, et al. Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study. Haemophilia. 2025. doi:10.1111/hae.70129

BibTeX
@article{Goudemand2025,
  author = {Goudemand, Jenny and Borel-Derlon, Annie and Claeyssens, Ségolène and Chambost, Hervé and Mourey, Guillaume and Harroche, Annie and Meunier, Sandrine and Henriet, Céline and Leroi, Thierry and Susen, Sophie and Repesse, Yohann},
  title = {Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70129}
}
Kostenlos starten →